// Biotech and Pharma Therapeutics
NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer
July 30, 2025 / AstraZeneca / dual immunotherapy / liver cancer treatment / NICE approval
NICE has approved AstraZeneca’s Imfinzi and Imjudo combo for advanced liver cancer, based on the HIMALAYA trial, offering improved overall survival and marking the UK’s first dual immunotherapy approval for hepatocellular carcinoma.
Vinay Prasad, controversial FDA official, abruptly departs agency
July 29, 2025 / Vinay Prasad / FDA resignation / gene therapy oversight / vaccine regulation / Duchenne treatment
Vinay Prasad abruptly resigned as FDA’s head of biologics after a brief, controversial tenure marked by stricter vaccine oversight, clashes over gene therapy approvals, and political backlash surrounding decisions on Duchenne muscular dystrophy treatments like Sarepta’s Elevidys.
Apellis counters Novartis with broad label for Empaveli in kidney disease
July 28, 2025 / Empaveli / rare kidney disease / FDA approval / C3G treatment / IC-MPGN therapy
Apellis’ Empaveli received FDA approval for both C3G and IC-MPGN, showing strong efficacy in kidney function stabilization and proteinuria reduction, and becoming the first approved treatment for IC-MPGN with a broader label than Novartis’ Fabhalta.
GE HealthCare and Ascension Partner to Enhance Clinical and Operational Outcomes Across National Network
July 28, 2025 / GE HealthCare / Ascension partnership / medical imaging technology / patient access improvement / healthcare innovation
GE HealthCare and Ascension have partnered to enhance clinical outcomes and patient access using advanced imaging and ultrasound technologies across Ascension’s national network, with a focus on delivering high-quality, equitable care, especially for underserved populations.
Quoin picks its cornerstone, shelving 2 assets to build around lead program
July 29, 2025 / Quoin Pharmaceuticals / Netherton syndrome / QRX003 approval / rare disease treatment / pipeline prioritization
Quoin Pharmaceuticals is halting development of QRX007 and QRX004 to focus on QRX003, its lead serine protease inhibitor in pivotal trials for Netherton syndrome, with plans to seek FDA approval and launch within 24 months.
// 4th Industrial Revolution
New platform predicts antibiotic resistance before it hits the clinics
July 30, 2025 / antibiotic resistance / metagenomic screening / drug development innovation / resistance-evasive antibiotics / environmental resistome
Researchers at Rockefeller University have developed a predictive platform that uses environmental metagenomic data to identify emerging antibiotic resistance genes, enabling the design of resistance-evasive drugs and potentially extending the clinical lifespan of new antibiotics.
Health tech investment bolstered by AI in H1: report
July 29, 2025 / health tech investment / AI in healthcare / digital health funding / healthcare VC trends / administrative automation
Despite overall healthcare investment slowing, health tech funding reached $8.2B in H1 2025, driven by strong interest in AI—particularly in administrative use cases—highlighting a shift toward sustainable, efficiency-focused digital solutions amid ongoing economic and policy uncertainties.
Home-based brain stimulation system uses AI to enhance concentration
July 29, 2025 / AI brain stimulation / cognitive enhancement / home neurotechnology / attention improvement / personalized tRNS
Researchers developed a home-based, AI-powered brain stimulation system using tRNS to enhance concentration. Personalized to individual traits, it significantly improved attention in users—especially those with lower baseline focus—without serious side effects or costly neuroimaging requirements.
AI algorithm identifies one-third of missed breast cancers in DBT screenings
July 29, 2025 / AI breast cancer / DBT screening / interval cancer detection / mammography AI / radiology innovation
An AI algorithm detected 32.6% of interval breast cancers missed by radiologists in DBT screenings, demonstrating its potential to reduce aggressive, undiagnosed cases and improve outcomes by serving as a second reader in breast cancer detection.
Cook Medical Launches New Imaging Division
July 29, 2025 / interventional MRI / Cook Medical iMRI / minimally invasive devices / radiation-free imaging / pediatric oncology
Cook Medical has launched a dedicated iMRI division to develop minimally invasive devices optimized for interventional MRI, enhancing precision and safety in complex procedures, particularly in pediatrics and oncology, while eliminating ionizing radiation exposure.
// Business & Markets
Investors whale on Cardiff, sinking stock after seeing updated colorectal cancer data
July 30, 2025 / onvansertib / colorectal cancer trial / PLK1 inhibitor / Cardiff Oncology / FDA discussions
Cardiff Oncology’s updated phase 2 data for onvansertib in RAS-mutated mCRC showed modest efficacy gains over standard care, falling short of key benchmarks. Despite investor skepticism, Cardiff plans to pursue FDA discussions for a potential registrational trial.
Madrigal pens $2B pact for CSPC’s preclinical GLP-1 with eye on Rezdiffra MASH pairing
July 30, 2025 / Madrigal Pharmaceuticals / GLP-1 agonist / Rezdiffra MASH therapy / SYH2086 deal / fatty liver disease
Madrigal Pharmaceuticals acquired global rights to CSPC’s preclinical GLP-1 agonist SYH2086 for $120M upfront, aiming to combine it with Rezdiffra to enhance efficacy in MASH treatment by addressing both weight loss and fibrosis in a once-daily oral therapy.
Ambience Healthcare Gains Unicorn Status & Snags $243M
July 29, 2025 / AI clinical documentation / Ambience Healthcare funding / healthcare automation / ambient scribe platform / clinician workflow AI
Ambience Healthcare secured $243M and unicorn status for its AI-powered documentation platform, designed to reduce clinician administrative burden and improve care delivery. Its integrated tools showed top performance in clinical settings, supporting complex specialties with high user adoption.
MapLight‘s mammoth Series D to fund schizophrenia and Alzheimer’s disease psychosis trials
July 29, 2025 / MapLight Therapeutics / muscarinic agonist / schizophrenia treatment / Alzheimer’s psychosis / Series D funding
MapLight Therapeutics raised $372.5M in Series D funding to advance ML-007C-MA, an oral M1/M4 muscarinic receptor agonist, into clinical trials for schizophrenia and Alzheimer’s disease psychosis, aiming to balance central efficacy with reduced peripheral side effects.
Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival
July 29, 2025 / Artbio funding / radiopharmaceutical therapy / prostate cancer drug / Pb-212 isotope / AB001 clinical trial
Artbio raised $132M to advance AB001, a Pb-212-based radiopharmaceutical targeting metastatic castration-resistant prostate cancer, into mid-stage trials. The startup is also scaling its isotope manufacturing platform to support clinical development and overcome radiopharma supply chain constraints.
// Legal & Regulatory
FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers
July 29, 2025 / FDA opioid action / 7-hydroxymitragynine regulation / kratom byproduct risk / youth opioid prevention / Controlled Substances Act
The FDA is recommending scheduling 7-hydroxymitragynine (7-OH), a potent opioid byproduct of kratom, under the Controlled Substances Act due to its abuse potential, especially in youth-targeted products, marking a step to prevent a new wave of opioid misuse.
VitalHub Announces Acquisition of Novari Health Inc.
July 29, 2025 / VitalHub acquisition / Novari Health software / patient flow management / referral management platform / healthcare digitalization
VitalHub has acquired Novari Health for $43.6M to strengthen its position in patient flow and referral management. Novari’s cloud-based platform enhances care coordination and waitlist management, with plans for international expansion, particularly in the UK healthcare market.
FDA takes U-turn on Sarepta’s Elevidys, backing Duchenne gene therapy again in ambulatory patients
July 28, 2025 / FDA reversal / Elevidys gene therapy / Duchenne muscular dystrophy / Sarepta Therapeutics / gene therapy safety
The FDA reversed its suspension on Sarepta’s Elevidys for ambulatory Duchenne muscular dystrophy patients after investigating safety concerns tied to liver failure deaths. Treatment remains paused in non-ambulatory patients as risk mitigation strategies are discussed.
FDA allows Sarepta to resume some Elevidys shipments
July 28, 2025 / Elevidys resumption / Duchenne gene therapy / Sarepta FDA update / ambulatory DMD patients / gene therapy safety
The FDA has allowed Sarepta to resume Elevidys shipments for ambulatory Duchenne muscular dystrophy patients after a safety-related pause. Non-ambulatory patients remain on hold due to deaths from liver failure, with risk mitigation discussions ongoing.
Rhode Island is the first state to provide menopause accommodations at work
July 28, 2025 / menopause workplace law / Rhode Island legislation / vasomotor symptoms accommodations / women’s health equity / Fair Employment Practices
Rhode Island is the first U.S. state to legally mandate workplace accommodations for menopause symptoms under its Fair Employment Practices Act, acknowledging the significant impact of vasomotor and related symptoms on women’s health and workplace equity.
// Research & Development
GSK’s anti-TIM-3 antibody flunks phase 3 trial as anti-TIGIT failure costs $629M
July 30, 2025 / GSK oncology failure / TIM-3 antibody trial / TIGIT drug write-off / cobolimab NSCLC trial / belrestotug phase 2
GSK’s anti-TIM-3 antibody cobolimab failed a phase 3 NSCLC trial, while its anti-TIGIT drug belrestotug also flopped, triggering a $629M write-off. The setbacks reflect broader industry challenges with TIM-3/TIGIT targets in solid and blood cancers.
Filgotinib meets phase 3 endpoint in axial spondyloarthritis trial
July 30, 2025 / filgotinib phase 3 / axial spondyloarthritis treatment / JAK1 inhibitor efficacy / OLINGUITO trial results / Alfasigma regulatory plans
Filgotinib met its primary endpoint in the phase 3 OLINGUITO trial for axial spondyloarthritis, showing efficacy across radiographic and non-radiographic forms with a consistent safety profile. Alfasigma plans regulatory submissions to expand its indications.
Neurogen Biomarking Virtual Care Ecosystem Cuts Time to Alzheimer’s Intervention by 4.5 Years
July 28, 2025 / Alzheimer’s early detection / blood biomarker testing / virtual cognitive assessment / p-tau217 testing / Neurogen virtual care
Neurogen’s virtual care ecosystem integrates in-home p-tau217 biomarker testing and digital cognitive assessments, cutting Alzheimer’s intervention time by 4.5 years. Pilot data validate accuracy and scalability, addressing critical delays in early AD detection and care access.
Your sleep schedule could be making you sick, says massive new study
July 29, 2025 / sleep regularity health / circadian rhythm disease / liver cirrhosis sleep risk / long sleep myth / UK Biobank sleep study
An 88,000-person study found that poor sleep regularity significantly increases risk for 92 diseases, including liver cirrhosis and gangrene. Objective data challenge myths around long sleep, emphasizing circadian stability as a critical, underrecognized determinant of chronic disease risk.
Columbia scientists turn yogurt into a healing gel that mimics human tissue
July 29, 2025 / yogurt-derived hydrogel / extracellular vesicles therapy / tissue regeneration biomaterial / injectable healing gel / regenerative medicine innovation
Columbia researchers developed a yogurt-derived hydrogel using extracellular vesicles (EVs) as both bioactive agents and structural components, promoting angiogenesis and tissue regeneration. The injectable, biocompatible material mimics human tissue and may revolutionize regenerative medicine and wound healing.
// Politics
Quest, Labcorp downplay ‘Big Beautiful Bill’ impact
July 29, 2025 / Medicaid policy cuts / lab testing volumes / Labcorp earnings outlook / Quest Diagnostics forecast / healthcare exchange impact
Despite Medicaid cuts in the “Big Beautiful Bill,” Labcorp and Quest Diagnostics expect minimal near-term impact on lab testing volumes, citing limited exposure to the healthcare exchange and time for states to adjust before major coverage losses occur.
Philips lowers expected tariff hit to 150M to 200M euros
July 29, 2025 / Philips tariff impact / U.S.-EU trade agreement / China healthcare market / medical device supply chain / 2025 earnings forecast
Philips lowered its projected 2025 tariff impact to €150M–€200M due to U.S.-EU and China trade agreements. The company is mitigating effects through supply chain adjustments while maintaining a cautious outlook on China amid ongoing sales declines.
Healthcare AI today: Woke AI pros & cons, AI in the states, Doximity’s free AI scribe, more
July 28, 2025 / healthcare AI regulation / maternal mortality AI / Doximity AI scribe / DEI in AI / Mayo Nvidia supercomputing
From Doximity’s free AI scribe to state-level AI regulation in Pennsylvania and global efforts to reduce maternal mortality, healthcare AI is rapidly evolving. Debates over “woke AI” and ethical use underscore the need for transparency, access, and responsible deployment.
Federal Cuts Only Worsen Health’s Ransomware Problem
July 29, 2025 / healthcare cybersecurity risk / ransomware in healthcare / federal health cuts / endpoint security failures / patient data protection
Federal healthcare cuts are compounding cybersecurity risks, as poor offboarding and outdated endpoint practices increase vulnerability to ransomware. With attacks rising 150% year-over-year, experts urge automated patching, continuous monitoring, and device lifecycle management to protect patient data and care continuity.
Experts Plead with RFK Jr. Not to Fire Key Preventive Health Panel
July 28, 2025 / USPSTF dismissal threat / RFK Jr. health policy / preventive care access / cancer screening guidelines / evidence-based medicine
Concerns are mounting over reports that HHS Secretary RFK Jr. may fire all U.S. Preventive Services Task Force members. Experts warn this could jeopardize access to evidence-based screenings and undermine decades of progress in preventive health policy and outcomes.